Photo for representational purpose only.
New Delhi, October 15
Drug firm AstraZeneca Pharma India on Thursday said it would launch its Acalabrutinib 100 mg capsules, used for treatment of various types of blood cancers, under the brand name 'Calquence' in the country on October 21.
The capsules are indicated for treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy and for treatment of patients with chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL), AstraZeneca Pharma India said in a filing to the BSE.
Shares of AstraZeneca Pharma India Ltd on Thursday closed 0.61 per cent lower at Rs 4,266.65 apiece on the BSE. PTI
Join Whatsapp Channel of The Tribune for latest updates.
Most Read In 24 Hours
Don't Miss
View All
Top News
Supreme Court to deliver verdict on PILs seeking 100% cross-verification of EVM votes with VVPAT on Friday
A Bench of Justice Sanjiv Khanna and Justice Dipankar Datta ...
Deeply biased: MEA on US report citing human rights violations in India
The annual report of the State Department highlights instanc...
Couldn't talk due to strictness of jail authorities: Amritpal's family after meeting him in jail
Their visit comes a day after Singh's legal counsel Rajdev S...
Centre grants 'Y' category security to Phillaur MLA Vikramjit Chaudhary and 2 other Punjab Congress rebels
The Central Reserve Police Force has been directed by the Mi...
